New Weekly Shot for Protein Leak from IgA Kidney Disease

Trutakna (atacicept-vymj) is a prescription medicine given as a subcutaneous injection once weekly. On the US Prescribing Information it is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether Trutakna slows kidney function decline over the long term in patients with IgAN. Continued approval may depend on confirmatory clinical benefit.

Distinct path — not this carton (fact-only): Other IgAN medicines (for example endothelin / angiotensin pathway products and immunosuppressants) have separate labels. Pediatric IgAN use is not established on this carton. Today’s US labelled weekly autoinjector door for adult primary IgAN proteinuria reduction is Vera Therapeutics Trutakna BLA 761486.

The FDA approved BLA 761486 on 7 July 2026 under accelerated approval. Manufacturer: Vera Therapeutics, Inc., Brisbane, CA; U.S. License Number 2386. Priority Review and Breakthrough Therapy designation noted on the FDA news page. Novel Drug Approvals for 2026 table row 24.

Where this is taking place

Commercial labelled door today: United States — FDA-labelled Trutakna for adults with primary IgAN at risk for disease progression, ordered through select specialty pharmacies that ship to the patient, with nephrology follow-up for infection monitoring and vaccine timing. This is a nephrology / kidney-care conversation — not a casual retail pickup and not a DIY import.

Outside the United States: As of this draft, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA ARTG listing, Swissmedic authorisation, or PMDA/MHLW licence for Trutakna / atacicept. Do not import on your own.

ORIGIN 3 — NCT04716231 — Randomized, double-blind, placebo-controlled Phase 2b/3 study in adults with biopsy-proven IgAN. Lead sponsor: Vera Therapeutics, Inc. CT.gov status at draft time: ACTIVE, NOT RECRUITING. Estimated enrolment 376. Actual start 29 Jun 2023; actual primary completion 15 May 2025; estimated study completion July 2028. Expanded access: CT.gov reports hasExpandedAccess: false on the record retrieved for this draft. Honesty: The USPI efficacy table uses an interim Week-36 analysis from this ongoing confirmatory program. Follow-up for long-term kidney function continues — that is not the same sentence as “walk into any pharmacy for Trutakna,” and it is not open new-enrolment recruitment for the pivotal cohort.

The practical commercial door in the US is a nephrology clinician who can confirm primary IgAN and proteinuria risk, write the labelled weekly autoinjector, connect specialty-pharmacy / Tru Support logistics, and monitor for infection — not treating ACTIVE_NOT_RECRUITING as open enrolment.

Approval matrix

Access by country

• United States: Ask a nephrology clinic about FDA-labelled Trutakna. Labelled 7 July 2026 (accelerated) to reduce proteinuria in adults with primary IgAN at risk for disease progression. Recommended dosage: 150 mg subcutaneously once weekly. Autoinjector intended for patient/caregiver home use after Instructions for Use training. Store refrigerated 2–8 °C in the original carton; protect from light; do not freeze or shake. If needed, room temperature up to 25 °C for a single period of 3 days (72 hours) — then do not return to the refrigerator; discard if unused. Carton of four autoinjectors: NDC 85052-101-04. Company patient support: Tru Support (specialty-pharmacy shipping to home; insurance / prior-authorisation help described on company patient materials). Suspected adverse reactions: Vera Therapeutics 1-833-633-8372 or FDA MedWatch 1-800-FDA-1088. No list price or copay dollars in this article. This is US commercial labelled supply through specialty pharmacy, not a DIY import.

• Canada: Trutakna authorisation not confirmed. Ask the Canadian nephrology clinic what legal paths exist in Canada when a Canadian Trutakna label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation not confirmed in this draft. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US autoinjector as a foreign carton.

Who is eligible (from the US label)

This is an adult primary IgAN proteinuria conversation on the Prescribing Information — weekly under-the-skin injection — not a pediatric carton and not a claim that long-term kidney-function slowing is already proven.

United States (USPI / Patient Information, revised July 2026):

• Indication: Reduce proteinuria in adults with primary IgAN at risk for disease progression.
• Accelerated approval: Based on proteinuria reduction; confirmatory clinical benefit still required.
• Recommended dosage: 150 mg SC once weekly.
• Missed dose: Take as soon as possible, then resume weekly dosing one week from the missed dose.
• Contraindication: Serious hypersensitivity to any ingredient in Trutakna.
• Warnings: Immunosuppression and increased infection risk — delay start during active infection; monitor; consider interrupting if infection becomes serious. Live vaccines not recommended within 30 days before start or during treatment.
• Most common adverse reactions (≥5% and > placebo): upper respiratory tract infection, injection-site reaction, injection-site erythema.
• Pregnancy / lactation: Limited human data; based on mechanism, may cause immunosuppression in an in-utero-exposed infant — discuss with clinician; report pregnancy exposure via Vera contact on label.
• Pediatrics: Safety and effectiveness not established.
• Geriatrics: Discuss with clinician; adequate numbers ≥65 not separately highlighted as a labelled geriatric indication change on sources used here.

ORIGIN 3 trial context (USPI): Adults with biopsy-proven IgAN, eGFR ≥30 mL/min/1.73 m², and proteinuria (24-hour UPCR ≥1 g/g or total urine protein ≥1 g/day), on a stable ACE inhibitor and/or ARB; 53% also on an SGLT2 inhibitor at baseline in the efficacy analysis set.

Not labelled on sources confirmed for this draft:

• Children and adolescents.
• Canadian, EU, UK, Japanese, Australian, or Swiss Trutakna marketing authorisations (not confirmed here).
• Proven long-term slowing of eGFR decline (still confirmatory under accelerated approval).
• Treating NCT04716231 follow-up as open commercial enrolment.

What the pivotal study showed (Prescribing Information)

Use the Prescribing Information for a prescription conversation. Journals are supportive reading.

ORIGIN 3 — NCT04716231 (USPI Study):

• Randomized, double-blind, placebo-controlled; Trutakna 150 mg or placebo once weekly SC.
• Efficacy analysis: first 203 patients who reached Week 36 (106 Trutakna / 97 placebo).
• Baseline (efficacy set): mean UPCR 1.5 g/g; mean eGFR 65 mL/min/1.73 m²; 60% had hematuria on urine microscopy; all on stable ACE inhibitor and/or ARB; 53% on SGLT2i. No rescue immunosuppressive therapy during the 36-week period in this analysis.

USPI Table 1 — Percent reduction in UPCR at Week 36:

Trial-status honesty: CT.gov status ACTIVE, NOT RECRUITING at draft time. The study supports the accelerated label and continues for confirmatory kidney-function endpoints — that is not open recruitment for a new pivotal cohort, and it is not automatic commercial enrolment everywhere.

How it is taken (US label — keep this exact)

Research team (from primary sources only)

• Applicant / manufacturer: Vera Therapeutics, Inc., Brisbane, CA — U.S. License 2386.
• Pivotal study sponsor: Vera Therapeutics, Inc. (NCT04716231 / ORIGIN 3).
• Journal primary investigator (ORIGIN Phase 3 publication cited on company HCP materials): Richard A. Lafayette, M.D. (Stanford) — Lafayette et al., N Engl J Med (doi:10.1056/NEJMoa2510198) as secondary reading; label numbers govern the access conversation.
• Patient support (company): Tru Support — specialty pharmacy path described on company patient materials; AE line 1-833-633-8372.
• Names and phones below are limited to what appears on the Prescribing Information, FDA news page, ClinicalTrials.gov, and clearly labelled company support materials.

Primary sources

1. Trutakna (atacicept-vymj) Prescribing Information — Vera Therapeutics, Revised 07/2026 — https://webfiles.veratx.com/docs/TRUTAKNA_Prescribing_Information.pdf (also Drugs@FDA label path for BLA 761486)
2. FDA news — FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy
3. FDA Novel Drug Approvals for 2026 (row 24) — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
4. ClinicalTrials.gov NCT04716231 (ORIGIN 3)
5. Company HCP / Tru Support patient pages (specialty-pharmacy logistics; not the label) — trutaknahcp.com / trutaknatrusupport.com